MiR-137 regulates the proliferation and invasion of glioma cells through EZH2/Wnt/β-catenin signaling pathway

被引:0
作者
Wang, Zong [1 ]
Yuan, Jiangwei [2 ]
Yang, Yang [1 ]
Li, Li [1 ]
Liu, Jidong [1 ]
Wang, Ying [3 ]
机构
[1] Zhumadian Cent Hosp, Dept Neurosurg, Zhumadian, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China
[3] Zhengzhou Univ, Dept Neurosurg, Affiliated Tumor Hosp, 127 Dongming Rd, Zhengzhou 450000, Peoples R China
关键词
Glioma; EZH2; miR-137; Wnt/beta-catenin; ZESTE HOMOLOG 2; MESENCHYMAL TRANSITION; MALIGNANT GLIOMAS; DOWN-REGULATION; CANCER; MICRORNAS; EZH2; METASTASIS; EXPRESSION; GROWTH;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRNAs) play critical roles in tumor development. In the present study, we explored the role of miR-137 in glioma progression. Our data showed that the miR-137 expression was reduced in glioma tissues and cell lines and reduced expression of miR-137 was corrected with tumor progression. Luciferase assay suggested that EZH2 is a direct target of miR-137, while EZH2 expression was inversely correlated with miR-137 expression in glioma tissues. Overexpression of EZH2 significantly reversed miR-137 mediated inhibition of proliferation and epithelial-mesenchymal transition (EMT), suggesting EZH2 upregulation is involved in the function of miR-137. Furthermore, our data showed that miR-137 inhibited the activity of Wnt/beta-catenin signaling pathway in glioma cells. In summary, our study provided that miR-137 could act as a tumor suppressor by targeting EZH2 in glioma cells, and might be useful for developing a novel therapeutic target for glioma.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 27 条
[1]   MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1) [J].
Bai, Yifeng ;
Liao, Hongzhan ;
Liu, Tianzhu ;
Zeng, Xiangping ;
Xiao, Faman ;
Luo, Luqiao ;
Guo, Hongbo ;
Guo, Linlang .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (03) :710-724
[2]   Epigenetic Silencing of miR-137 Is an Early Event in Colorectal Carcinogenesis [J].
Balaguer, Francesc ;
Link, Alexander ;
Lozano, Juan Jose ;
Cuatrecasas, Miriam ;
Nagasaka, Takeshi ;
Boland, C. Richard ;
Goel, Ajay .
CANCER RESEARCH, 2010, 70 (16) :6609-6618
[3]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[4]   miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42 [J].
Chen, Qingjiang ;
Chen, Xiaobing ;
Zhang, Mingzhi ;
Fan, Qingxia ;
Luo, Suxia ;
Cao, Xinguang .
DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (07) :2009-2016
[5]   EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin-Dependent Hepatocarcinogenesis [J].
Cheng, Alfred S. L. ;
Lau, Suki S. ;
Chen, Yangchao ;
Kondo, Yutaka ;
Li, May S. ;
Feng, Hai ;
Ching, Arthur K. ;
Cheung, Kin F. ;
Wong, Hoi K. ;
Tong, Joanna H. ;
Jin, Hongchuan ;
Choy, Kwong W. ;
Yu, Jun ;
To, Ka F. ;
Wong, Nathalie ;
Huang, Tim H. -M. ;
Sung, Joseph J. Y. .
CANCER RESEARCH, 2011, 71 (11) :4028-4039
[6]   Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer [J].
Choi, Jung Hye ;
Song, Young Soo ;
Yoon, Jin Sun ;
Song, Kang Won ;
Lee, Young Yiul .
APMIS, 2010, 118 (03) :196-202
[7]   Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis [J].
Christiansen, Jason J. ;
Rajasekaran, Ayyappan K. .
CANCER RESEARCH, 2006, 66 (17) :8319-8326
[8]   Extensive modulation of a set of microRNAs in primary glioblastoma [J].
Ciafrè, SA ;
Galardi, S ;
Mangiola, A ;
Ferracin, M ;
Liu, CG ;
Sabatino, G ;
Negrini, M ;
Maira, G ;
Croce, CM ;
Farace, MG .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 334 (04) :1351-1358
[9]   Wnt/β-Catenin Signaling and Disease [J].
Clevers, Hans ;
Nusse, Roel .
CELL, 2012, 149 (06) :1192-1205
[10]   Targeting protein kinase C: New therapeutic opportunities against high-grade malignant gliomas? [J].
da Rocha, AB ;
Mans, DRA ;
Regner, A ;
Schwartsmann, G .
ONCOLOGIST, 2002, 7 (01) :17-33